TCRX Q2 2024 Earnings — TScan Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

TCRXTScan Therapeutics, Inc.

$69M

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$536,000-83.0% YoY

Gross Profit

$536,000100.0% margin

Operating Income

-$34M-6364.6% margin

Net Income

-$32M-5906.9% margin

EPS (Diluted)

$-0.28

QoQ Revenue Growth

-5.3%

Cash Flow

Operating Cash Flow

-$26M

Free Cash Flow

-$27M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$375M

Total Liabilities

$120M

Stockholders' Equity

$255M

Cash & Equivalents

$242M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$536,000	$3M	-83.0%
Gross Profit	$536,000	$3M	-83.0%
Operating Income	-$34M	-$25M	-38.6%
Net Income	-$32M	-$24M	-31.7%